CHRONIC SPONTANEOUS URTICARIA (CSU)
Clinical trials for CHRONIC SPONTANEOUS URTICARIA (CSU) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC SPONTANEOUS URTICARIA (CSU) trials appear
Sign up with your email to follow new studies for CHRONIC SPONTANEOUS URTICARIA (CSU), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ICP-332 aims to soothe stubborn hives when antihistamines fail
Disease control Recruiting nowThis study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot could tame stubborn hives that antihistamines Can't
Disease control Recruiting nowThis Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Biosimilar switch for asthma and hives under Real-World study
Disease control Recruiting nowThis study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 1…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Sponsor: Celltrion HealthCare France • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill shows promise for stubborn hives in Head-to-Head trial
Symptom relief Recruiting nowThis study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Scientists probe hidden IgE variants to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study looks at different forms of IgE (a protein involved in allergic reactions) in healthy volunteers and people with conditions like severe allergies, chronic hives, mastocytosis, and immune deficiencies. Researchers aim to understand how these IgE variations relate to hea…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Sponsor: KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC